Cyclin-dependent kinase 5(CDK5) in complex with its activator, p35 (protein of 35 kDa), is essential for early neurodevelopment in mammals. However, endogenous cleavage of p35 to p25 is associated with neuron death and neurodegenerative disease. Here we show that a peptide (p10′) encoding the N-terminal domain of p35 protects against CDK5/p25-induced toxicity in neurons. p10′ also prevented the death of neurons treated with the neurotoxin, 1-methyl-4-phenylpyridinium (MPP + ), which induces conversion of endogenous p35 to p25, and Parkinson disease (PD)-like symptoms in animals. MPP + induces CDK5/p25-dependent phosphorylation of peroxiredoxin 2 (Prx2), resulting in inhibition of its peroxireductase activity and accumulation of reactive oxygen species (ROS). We found that p10′ expression inhibited both Prx2 phosphorylation and ROS accumulation in neurons. In addition, p10′ inhibited the p25-induced appearance of antigen of the Ki67 antibody (Ki67) and phosphohistone H2AX (γH2AX), classic markers of cell cycle activity and DNA double-strand breakage, respectively, associated with neuron death. Our results suggest that p10 (protein of 10 kDa) is a unique prosurvival domain in p35, essential for normal CDK5/p35 function in neurons. Loss of the p10 domain results in CDK5/p25 toxicity and neurodegeneration in vivo.
DK5 (cyclin-dependent kinase 5) kinase activity was originally identified as a tau kinase implicated in Alzheimer's disease (AD) progression (1) and independently as a unique cell cycle kinase homolog exhibiting CDK1-like substrate specificity in brain (2) . The active kinase was found to be a heterodimer of CDK5 (3, 4) bound to p25 (5), the latter which was generated from a larger precursor, p35 (6) (7) (8) , by calpain cleavage (9) (10) (11) . Binding of p35 or p25 (12) , or other activators including p39/p29 (13) or cyclin I (14) , to CDK5 is essential for protein kinase activity. However, whereas CDK5/p35 is essential for normal embryological development of mammalian brain (15) (16) (17) , CDK5/p25 induces cell death and is associated with neuropathology (18) . Proteolytic conversion of p35 to p25 has been reported to be associated with AD in humans (18, 19) as well as with animal models of Alzheimer's disease (20) (21) (22) , Parkinson disease (PD) (23, 24) , amyotrophic lateral sclerosis (25) , and other neurodegenerative disorders.
The relative catalytic activity of CDK5/p35 compared with CDK5/p25 in vivo is not known. In vitro, however, the activities of both enzymes in purified form are equivalent (26) . Thus, the simple assumption is that conversion of p35 to p25 does not alter the intrinsic kinase activity of CDK5, and therefore altered kinase activity does not explain the link between p35 cleavage and the toxicity of CDK5/p25. Both enzymes, however, display dramatic differences in subcellular distribution, potentially explaining distinct sets of substrates targeted by either enzyme in vivo (20) . For example, CDK5/p35 has reportedly been localized to the cell periphery (18) , cytoplasm, and/or nucleus (27, 28) and, in general, targets cytoskeletal, cell adhesion, membrane cycling, axonal transport, synapse, and neuronal migration-related proteins (29) . By comparison, CDK5/p25 has been reported to be perinuclear (18) and nuclear (30) and has been shown to target a number of substrates linked to apoptosis (23, (31) (32) (33) (34) .
The neurotoxic phenomenon associated with accumulation of p25 has led previous studies to focus exclusively on the mechanism of action of CDK5/p25, whereas the role of the cleaved p35 Nterminal domain (p10) remains unknown. Here we provide evidence that p10 is a unique prosurvival sequence that is essential and alone sufficient to prevent CDK5/p25-induced cell death.
Results
Overexpression of p10′ Protects Neurons from Cell Death. Transfection of CDK5/p25 into COS7 (monkey kidney cell line) cells causes chromatin condensation and cell death, in contrast to cells transfected with CDK5/p35 whose nuclei appear normal and healthy ( Fig. 1A and ref. 18 ). Because p25 differs from p35 by only the N-terminal p10 sequence in p35 (6-8), we asked if this sequence when expressed as a separate polypeptide could protect cells from CDK5/p25-induced cell death. We engineered a peptide corresponding to p10 (amino acids 1-98 of p35) fused to the first 40 amino acids of p25 (amino acids 99-138 of p35) so as to accommodate any putative proteins that may potentially require determinants in both p10 and the corresponding region of p25 for binding. The 40-aa segment of p25 does not interact with residues in CDK5 (35) nor does it affect kinase activity (36) . The resulting construct, p10′ (p35 ) (Fig. S1 ), when stably expressed in COS7 cells ( Fig. 1 A-C) or human SH-SY5Y (human neuroblastoma cell line) neuroblastoma cells (Fig. 1D ) completely prevented cellular toxicity induced by CDK5/p25. Transient p10′ expression also prevented CDK5/p25-induced cell death in rat primary neurons (Fig. 1E ). These experiments reveal a unique function for the p10 domain of p35, which when expressed in trans can protect against CDK5/p25-induced cell death in both non-neuronal and neuron-related cell systems.
MPTP is a chemical neurotoxin that induces PD-like symptoms when administered to mammals. The toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) owes to its permeability to the blood-brain barrier followed by its oxidation in glial cells to MPP + , the active form of the toxin which targets complex I of the electron transport chain in neurons (37, 38) . Electron transport inhibition results in both an energy crisis in the cell and generation of reactive oxygen species (ROS), both of which may contribute to neuron degeneration (39) . Interestingly, MPTP causes conversion of endogenous p35 to p25 in neurons of the substantia nigra in mice (31) , suggesting that aberrant CDK5/p25 activity may contribute to MPP + -induced neurotoxicity. We found that treatment of neurons with MPP + caused redistribution of anti-p25 staining from being predominantly membrane-bound to nuclear/perinuclear localization (Fig. S2A ), followed by cell death. The redistribution is consistent with the normal membrane association of p35 versus the nuclear localization of p25 when separately overexpressed in COS7 cells (Fig. S2B) . Western blot analysis showed that MPP + caused conversion of p35 to p25 within the time frame of subcellular redistribution ( Fig. 2A) . p10′ cells were coinfected with LV-CDK5 + LV-p25 at decreasing multiplicity of infection (MOI) of both, and cell viability was assessed by using the CellTiter-Glo Assay (Promega) for cellular ATP. (E) Rat primary cortical neurons were infected with LV-p10′ or LV-GFP, then subsequently coinfected with LV-CDK5 + LV-p25. Cell viability was measured 48 h after coinfection by MTT reduction. More than 90% of cells were neurons. All error bars represent SD about the mean from three separate experiments. Owing to the link between MPP + toxicity and conversion of endogenous p35 to p25, we asked if p10′ could protect neurons from MPP + toxicity. MPP + toxicity is classically associated with death of dopaminergic neurons because these neurons specifically concentrate MPP + through the dopamine transporter (40, 41) , whereas at higher concentrations, MPP + is also toxic to cortical neurons (23). We found that primary cortical neurons infected with lentivirus (LV)-p10′ were significantly protected from MPP + toxicity compared with neurons that were infected with a LV-GFP control protein, measured by the presence of neuronal-specific tubulin (Fig.  2B) , which reflects the retention of specifically live neurons in the cell culture well (dead neurons are washed away). Similar results were obtained using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, which measures active electron transport (Fig. 2C) . The protective action of p10′ observed in these experiments is consistent with the possible involvement of CDK5/ p25 in MPP + toxicity.
Proteasome Inhibitor MG132 Protects Against Cell Death. Given that p10′ can protect against CDK5/p25-induced toxicity, we asked why cleavage of p35 to p25 is associated with neuron death, because p10 is a product of this reaction. We were unable to detect endogenous p10 in neuronal extracts in response to MPP + treatment by Western blot analysis, which led us to hypothesize that p10 may be rapidly degraded. We thus tested if inhibition of the proteosome may promote p10 accumulation. Neurons were treated with the proteosomal inhibitor, MG132. However, under these conditions, endogenous p10 still could not be detected by Western analysis. We thus turned to ask if MG132 may affect the stability of overexpressed p10′. Primary neurons were infected with LV-p10′ for 72 h, then treated with MG132 for a further 6 h. During the time of MG132 treatment, p10′ was seen to significantly accumulate (Fig.  3A) by Western analysis. This supports but does not prove that endogenous p10 may behave similarly.
To investigate directly the effect of MG132 on endogenous p10, we monitored p10 in neurons by immunocytochemical staining after treatment with MPP + and MG132, either alone or in combination (Fig. 3B ). Untreated neurons (control) displayed anti-p10 staining that was localized to the cell periphery and to neuronal processes, consistent with the staining of p35 at the plasma membrane (18) . Upon treatment with MPP + , anti-p10 staining was effectively abolished, consistent with rapid p10 proteolytic degradation. However, in neurons treated with both MPP + and MG132 together, anti-p10 staining in neuronal processes was preserved, consistent with p35 cleavage and protection of p10 from degradation by MG132. Antip25 staining did not track with anti-p10 staining (Fig. 3B, Insets) , confirming that p35 was cleaved and that the anti-p10 signal was due to p10, not p35. These data suggest that MG132 is not acting via inhibition of p35 cleavage.
Given that MG132 can promote endogenous p10 accumulation in neurons, we tested if MG132 could protect neurons from MPP + -induced toxicity. Neurons were observed to undergo significant cell death after 24 h of MPP + treatment. However, when cotreated with both MPP + and MG132, neuron viability was significantly increased (Fig. 3C ). These data, in all, strongly suggest that MPP + causes cleavage of CDK5/p35 to generate CDK5/p25 and p10, and in the presence of MG132, p10 accumulates conferring protection of cells from CDK5/p25-associated cell death.
CDK5/p35 and CDK5/p25 display identical kinase activity in vitro (26) , yet CDK5/p25 is toxic to cells, whereas CDK5/p35 is not. Therefore, it is proposed that p10, which corresponds to the Nterminal domain of p35, intrinsically serves to suppress toxicity in CDK5/p35 in normal neurons. We asked if the neuroprotective activity exhibited by free p10′ may be specific to CDK5/p25-associated toxic processes. Staurosporin is toxic to neurons, but its toxicity is not mediated by a CDK5/p25-associated process. When neurons were treated with staurosporin, significant cell death was apparent. However, in contrast to death induced by MPP + , p10′ provided no significant protection to neurons treated with staurosporin (Fig. S3) . ) by CDK5/p25 in response to MPP + treatment inhibits Prx2 activity, contributing to cell death (23) . We asked if the protective action of p10′ may possibly involve Prx2-dependent ROS scavenging.
We tested the phosphorylation state of Prx2 in neurons using a pThr 89 -specific antibody in response to CDK5/p25 and p10′ expression. We found that CDK5/p25 induced the phosphorylation of Prx2 and that this phosphorylation was prevented by expression of p10′ (Fig. 4A ). In addition, we measured ROS levels by 2′-7′-dichlorofluorescein (DCF) fluorescence emission and found that CDK5/p25-dependent Prx2 phosphorylation correlated with increased ROS accumulation. This accumulation of ROS was prevented by p10′ (Fig. 4 B and C) . We then tested if p10′ protected against Prx2 phosphorylation and ROS accumulation when toxicity was induced by MPP + .
Treatment of control neurons with MPP
+ resulted in both a timedependent phosphorylation of Prx2 at Thr 89 ( Fig. 4D ) and increased ROS generation (Fig. 4F) . In contrast, overexpression of p10′ in MPP + -treated neurons prevented both Prx2 phosphorylation (Fig. 4E ) and ROS accumulation (Fig. 4F) . Because a direct correlation between Prx2 activity and neuron survival has previously been demonstrated (23), our finding that p10′ can directly modulate the Prx2 pathway points to a possible cellular basis for p10's protective action, although the direct target of p10 remains unknown.
Appearance of Ki67 and γH2AX Is Prevented by p10′. Neuronal apoptosis has been linked to reactivation of the cell cycle machinery. Accordingly, neurons and postmitotic cells in general actively repress cell cycle control proteins (43) , and expression of p25 in mouse forebrain leads to transcriptional alterations in both cell cycle and DNA repair genes (44) . We therefore asked if p10′ would antagonize the effects of p25 on the appearance of cell cycle and/or DNA repair marker proteins. Rat cortical neurons were infected with p25 or p25 + p10′, and the number of neurons expressing the cell cycle marker, Ki67, was counted. In response to p25 expression, Ki67 was significantly up-regulated (Fig. 5A) , suggesting that cell cycle activity was induced as expected. In the presence of p10′, however, the p25-induced cell cycle activity was suppressed, apparent as a decrease in neuronal Ki67 expression to base-line levels. This suggests that the ability of p10′ to inhibit CDK5/p25-induced cell death may be tightly linked to its ability to inhibit aberrant cell cycle activity.
We found also that p25 induced the phosphorylation of neuronal H2AX, a marker of DNA damage, and that p10′ attenuated this phosphorylation (Fig. 5B) .
The data, overall, suggests that the known cell death pathways activated by CDK5/p25 can be suppressed by p10′, consistent with p10's ability to specifically protect against CDK5/p25-induced neuron death.
Discussion
Cleavage of endogenous p35 to form p25, and demonstration that CDK5/p25 is toxic to neurons, was first described by Patrick et al. (18) followed by others (9) (10) (11) . Since that time, attention has focused extensively on CDK5/p25, whereas the significance of the Nterminal proteolytic fragment, p10, has not been investigated.
Herein we report that free p10′ (Fig. S1 ) prevents the toxicity induced by CDK5/p25 in neurons, conferring the degree of cell viability normally associated with CDK5/p35. A number of observations suggest that the mechanism of protection by p10′ is not a simple reconstitution of p35 function. Principally, Prx2 is phosphorylated by CDK5/p35 in SY5Y cells (Fig. 4A) . Further, this phosphorylation is inhibited by p10′ (Fig. 4A) . Lastly, we have been unable to demonstrate p10′ binding to CDK5/p25 despite extensive effort by in vitro pull-down assays. These data suggest that the mechanism of action of p10′ may depend upon an intact cellular environment. It is unlikely that the p25 region (p35 ) of p10′ directly disrupts interaction between p25 and CDK5, because these residues in p25 do not interact with CDK5 (35) . In addition, the proteosome inhibition experiments suggest that the bona fide 98-aa p10 fragment (p35 ) itself, when induced to accumulate in cells, is functional (Fig. 3C) . The fact that p10′ inhibits CDK5/p25 phosphorylation of Prx2 in vivo (Fig. 4A) suggests that the mechanism of action of p10′ may depend upon one or more unknown cellular factors. One possibility is the requirement of a cellular factor for formation of an inhibitory complex comprising endogenous p10, p25, CDK5, and possibly Prx2 or another endogenous substrate. The mechanism by which p10 affects cell viability is not known. Chew et al. reported that p10 is in fact toxic when overexpressed in the neuroblastoma cell line neuro-2A (45) . In contrast, we consistently found that p10′ had no effect on cell viability when stably expressed in COS7 or SH-SY5Y cells or when transiently expressed in rat cortical neurons. To address this inconsistency directly, we obtained the p10 expression constructs used in the studies of Chew et al. (provided by R. Z. Qi, Hong Kong University of Science and Technology, Hong Kong). Using their constructs, we found that p10 expression was not toxic when tested in SH-SY5Y neuronal cells (Fig. S4) . In fact, p10 protected against CDK5/p25 toxicity (Fig. S4) , consistent with all results that we have observed and which we report herein. The source of the discrepancy between our results and those of Chew et al. (45) remains unknown. Our own data, which show that p10 is a prosurvival sequence, explain how degradation of the N-terminal p10 domain of p35 leads to CDK5/p25 toxicity. On the other hand, if both CDK5/ p25 and p10 were intrinsically toxic, as proposed by Chew et al., it is difficult to rationalize how toxicity would be averted in the CDK5/ p35 molecule present in normal neurons.
p25 has been implicated in Alzheimer's disease (46, 47) , and inhibitors of CDK5/p25 are presently being sought as potential therapeutics of neurodegeneration. Because it is reported that CDK5/p35 may be essential in adult neurons to prevent cell cycle reentry and death (48) , it is imperative that an inhibitor molecule effectively discriminates between CDK5 bound to p25 as opposed to p35. However, as with most kinase inhibitors that act competitively with ATP or conceivably the protein substrate, all known conventional inhibitors of CDK5 are expected to target both CDK5/p25 and CDK5/p35, because both enzymes exhibit comparable active site structures based on their similar catalytic efficiencies toward histone or tau protein (26) . Our studies herein suggest that p10 may represent a unique class of CDK5 inhibitor capable of preventing the toxic effects of CDK5/p25 without affecting the normal function of CDK5/p35.
Materials and Methods
Antibodies. C-19 is directed toward the p25 domain of p35 and recognizes p25 or p35. N-20 is directed to the p10 domain of p35 and recognizes p10 or p35. C-19, N-20, C-8 (CDK5), J-3 (CDK5), 9E10 (c-myc) anti-GFAP, anti-MAP2 and anti-GFP are from Santa Cruz. Other antibodies used were: antitubulin (Sigma,), anti-Prx2 (monoclonal; Abcam), and Alexa-labeled secondary antibodies (Invitrogen); anti-Ki67 (BD Bioscience); anti-γH2AX (anti-pH2AX) (Upstate Biotech); Tuj-1 (Neuromics); anti-IgG (Jackson Immunoresearch); and anti-TH (Immounostar). Anti-Prx2 (pThr 89 ) polyclonal antibody was a gift from David Park, University of Ottawa, Ottawa.
Primary Neuronal Cell Culture. All animal protocols were IACUC approved by the animal resource center at the University of California, Santa Barbara. Whole brains were collected from rat E18 embryos. Forebrains were dissected in medium [1× HBSS (Gibco), 10 mL Hepes (pH 7.3), 10 mL 100× Pen/Strep (Gibco)], and the meninges and blood vessels were removed. Cortex was then removed from the forebrain and incubated with 25 mg/mL trypsin at 37°C for 10-15 min, then dispersed by repeated aspiration with a Pasteur pipette. After trypsinization, tissue was then homogenized in 10% glial MEM (425 mL MEM; Gibco), 15 mL 20% glucose, 5 mL 100× Pen/Strep, and 50 mL horse serum). Cells were counted and plated in 10% glial MEM in Nunc 60-mm dishes (5 × 10 6 cells per well) for Western blot or on pretreated cover glass (Fisher) (2-5 × 10 5 cells per well) for immunocytochemistry and survival assay. After neurons were completely seeded, they were maintained in neurobasal media supplemented with B-27 and N2 nutritional supplements, 0.5 mM glutamine, and 0.05 mg/mL pen/strep (all from Invitrogen) for 7-10 d before experimental use. After 3 d in culture, cells were treated with 1 μM cytosine arabinocide to enrich for neurons by killing proliferative cells.
Forty-eight hours after LV transduction, cultures were subjected to 50 μM MPP + or DMSO as control. In select experiments, neurons were also pretreated with 10 μM MG132 (Sigma), the proteosome inhibitor for 1 h, and then cotreated with 20 μM MPP + or control. Confocal imaging was performed on an Oympus Fluoview FV500 microscope using an Olympus UPLFLN 40× NA = 1.3 oil-immersion objective. Z stacks (0.2-μm sections) were deconvoluted using softWoRx (Applied Precision), projected for maximum intensity and imported into Adobe Photoshop CS4 for further processing. Image intensities for each antibody were scaled identically.
Cell Viability Assay. After immunostaining, COS7 cells were labeled with the DNA dye DAPI (Invitrogen), and double-transfected COS7 cells were scored for healthy or apoptotic nuclear morphology. Cells were scored positive if they had a pyknotic and/or fragmented nucleus. Representative graphs are shown for experiments where 150 or 300 cells were scored. All experiments were done at least three times. Neuronal cell viability was measured by reduction of MTT or by Guava ViaCount viability assay. The MTT assay was performed by adding MTT (0.5 mg/100 μL per well) to each well, followed by incubation for 10 min at 37°C under 5% CO 2 . At the end of the assay, 1 mL of DMSO was added to each well to extract the formazan produced. Formazan was measured by absorbance at 540 nm.
For Guava ViaCount viability assay, 225 μL of ViaCount reagent was added to 25 μL of cell suspension (1 × 10 5 cells/mL). The cells were stained for at least 5 min and the viability measured by Guava EasyCyte Flow Cytometry (Millipore).
Cell viability of SH-SY5Y cells was measured by using CellTiter-glo Luminescent Cell Viability Assay kit (Promega) following manufacturer protocol. Briefly, cells were plated in 96-well plates at a density of 1 × 10 3 per well. A total of 50 μL of reagent was added into per 50 μL of culture medium with cells. The culture plates were incubated at room temperature for 10 min. The luminescent signal was measured with a microplate reader.
Reactive Oxygen Species Imaging. Cortical neurons were incubated with 10 mM H 2 DCFDA-AM for 20 min at 37°C and washed three times with neurobasal (NB) medium. The fluorescence signal of the oxidized product DCF (2′7′dichlorodihydrofluorescein) was observed by an inverted fluorescent microscope equipped with a 100 W xenon lamp and filter (for oxidized DCF, excitation = 488 nm and emission = 510 nm). DCF + cells were quantified by Guava EasyCyte Flow Cytometry (Millipore).
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